Endocyte Inc (NASDAQ:ECYT)

Data as of Jan 23
 -0.06 / -1.16%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Endocyte, Inc. is a biopharmaceutical company, which develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.

Contact Information

Endocyte, Inc.
3000 Kent Avenue
West Lafayette Indiana 47906
P:(765) 463-7175
Investor Relations:



Mutual fund holders22.82%
Individual stakeholders21.96%
Other institutional17.36%

Top Executives

P. Ron EllisPresident, Chief Executive Officer & Director
Michael A. ShermanChief Operating & Financial Officer
Philip S. LowDirector & Chief Science Officer
Christopher P. LeamonVice President-Research & Development
Binh NguyenVice President-Medical Affairs

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.